Nathan Robinson

Nathan Robinson

Partner

Nathan Robinson is a partner in the Salt Lake City oﬀice of Wilson Sonsini Goodrich & Rosati, where he specializes in corporate and securities law, including general corporate representation, public oﬀerings, private placements, and mergers and acquisitions. He has signiﬁcant experience in counseling publicly held companies on disclosure matters and complex securities laws issues. He regularly works with emerging growth, technology, and life sciences companies, both public and private, as well as investment banks, venture capital funds, and private equity ﬁrms.

Prior to joining the ﬁrm, Nathan practiced in the corporate group at Latham & Watkins and was Sr. Director of Legal, Securities at Lucid Software Inc. In addition to his legal practice, Nathan enjoys teaching law and business school students and most recently taught a course on structuring, negotiating, and drafting transaction agreements at the University of Texas School of Law as an adjunct faculty member during 2019 and 2021.

Prior to law school, Nathan was a consultant with The Gallup Organization.

Experience

Prior to law school, Nathan was a consultant with The Gallup Organization.

Education

J.D., University of Texas School of Law, 2009
M.B.A., University of Utah, 2004
B.A., International Studies, Brigham Young University, 2001

Admissions

State Bar of California
State Bar of Massachusetts
State Bar of Texas
State Bar of Utah

Credentials

Education

J.D., University of Texas School of Law, 2009
M.B.A., University of Utah, 2004
B.A., International Studies, Brigham Young University, 2001

Admissions

State Bar of California
State Bar of Massachusetts
State Bar of Texas
State Bar of Utah

Select Matters

Life Science Sector

Represented the issuer for the initial public offering of Recursion Pharmaceuticals
Represented the issuer for the initial public offering of Kinnate Biopharma Inc.
Represented the underwriters for the initial public oﬀering of the ordinary shares of a medical device company
Represented Lumos Pharma in its reverse merger with NewLink Genetics Corporation and listing on Nasdaq, at-the-market offerings, and Exchange Act reporting matters
Represented Savara in underwritten follow-on offerings, at-the-market offerings, PIPEs, and Exchange Act reporting matters
Represented BioCardia in its Nasdaq uplisting, public offering of common stock and warrants, registered direct offerings, at-the-market offering, equity line of credit offering, and Exchange Act reporting matters
Represented a public medical device company in the sale of its scope business
Represented the underwriters in a follow-on public oﬀering of common stock of a biotechnology company focused on neurologic- and endocrine-related disorders
Represented a specialty pharmaceutical company commercializing proprietary branded prescription drugs in a follow-on public oﬀering of its common stock
Assisted a public biotechnology company in Exchange Act reporting matters
Represented Stingray Therapeutics in its Series Seed Preferred Stock financing
Represented Stingray Therapeutics in its convertible note financing
Represented the investor in a Series A Preferred Stock investment in Keystone Bio
Represented the investor in a Series A Preferred Stock investment in Abrexa Pharmaceuticals
Represented a specialty pharmaceutical company developing immunotherapies for cancer treatment in its Series A preferred stock ﬁnancing
Represented a specialty pharmaceutical company developing drugs for respiratory therapies in its Series A preferred stock ﬁnancing
Represented a specialty pharmaceutical company developing a needle free patch for pain medication in its Series A preferred stock ﬁnancing
Represented a specialty pharmaceutical company developing cancer treatment drugs in its Series A preferred stock ﬁnancing

Software/Technology Sector

Represented the issuer for the direct listing of Roblox Corporation
Represented the underwriters for the initial public offering of C3.ai Inc.
Represented the issuer for the initial public offering of trivago N.V.
Represented the underwriters for the initial public oﬀering on Nasdaq Copenhagen of a Danish payment processing company
Represented RealPage in follow-on equity offerings and convertible debt offering
Represented the underwriters for convertible debt offerings of Okta
Represented the underwriters for Q2 Holdings follow-on equity and convertible debt offerings
Represented National Instruments Corporation in its acquisition of Israel-based Optimal Plus
Represented National Instruments Corporation in its investment in Monodrive
Represented National Instruments Corporation in the disposition of AWR Corporation, its subsidiary
Represented BigCommerce in its acquisition of Feedonomics
Represented Icon Technologies in its Series Seed preferred stock ﬁnancing
Represented Secturion Systems in its Series A and B preferred stock ﬁnancings
Represented Conversable, Inc. in its sale to LivePerson
Represented a global payment processing company in its preferred stock ﬁnancing
Represented a software company that developed a software asset management platform in the sale of a large minority interest to a private equity ﬁrm
Represented a private equity ﬁrm in its acquisition of a healthcare software solutions company
Represented a private equity ﬁrm in its acquisition of a company providing software to facilitate forms completion, data collection, and process workﬂow

Matters

Select Matters

Life Science Sector

Represented the issuer for the initial public offering of Recursion Pharmaceuticals
Represented the issuer for the initial public offering of Kinnate Biopharma Inc.
Represented the underwriters for the initial public oﬀering of the ordinary shares of a medical device company
Represented Lumos Pharma in its reverse merger with NewLink Genetics Corporation and listing on Nasdaq, at-the-market offerings, and Exchange Act reporting matters
Represented Savara in underwritten follow-on offerings, at-the-market offerings, PIPEs, and Exchange Act reporting matters
Represented BioCardia in its Nasdaq uplisting, public offering of common stock and warrants, registered direct offerings, at-the-market offering, equity line of credit offering, and Exchange Act reporting matters
Represented a public medical device company in the sale of its scope business
Represented the underwriters in a follow-on public oﬀering of common stock of a biotechnology company focused on neurologic- and endocrine-related disorders
Represented a specialty pharmaceutical company commercializing proprietary branded prescription drugs in a follow-on public oﬀering of its common stock
Assisted a public biotechnology company in Exchange Act reporting matters
Represented Stingray Therapeutics in its Series Seed Preferred Stock financing
Represented Stingray Therapeutics in its convertible note financing
Represented the investor in a Series A Preferred Stock investment in Keystone Bio
Represented the investor in a Series A Preferred Stock investment in Abrexa Pharmaceuticals
Represented a specialty pharmaceutical company developing immunotherapies for cancer treatment in its Series A preferred stock ﬁnancing
Represented a specialty pharmaceutical company developing drugs for respiratory therapies in its Series A preferred stock ﬁnancing
Represented a specialty pharmaceutical company developing a needle free patch for pain medication in its Series A preferred stock ﬁnancing
Represented a specialty pharmaceutical company developing cancer treatment drugs in its Series A preferred stock ﬁnancing

Software/Technology Sector

Represented the issuer for the direct listing of Roblox Corporation
Represented the underwriters for the initial public offering of C3.ai Inc.
Represented the issuer for the initial public offering of trivago N.V.
Represented the underwriters for the initial public oﬀering on Nasdaq Copenhagen of a Danish payment processing company
Represented RealPage in follow-on equity offerings and convertible debt offering
Represented the underwriters for convertible debt offerings of Okta
Represented the underwriters for Q2 Holdings follow-on equity and convertible debt offerings
Represented National Instruments Corporation in its acquisition of Israel-based Optimal Plus
Represented National Instruments Corporation in its investment in Monodrive
Represented National Instruments Corporation in the disposition of AWR Corporation, its subsidiary
Represented BigCommerce in its acquisition of Feedonomics
Represented Icon Technologies in its Series Seed preferred stock ﬁnancing
Represented Secturion Systems in its Series A and B preferred stock ﬁnancings
Represented Conversable, Inc. in its sale to LivePerson
Represented a global payment processing company in its preferred stock ﬁnancing
Represented a software company that developed a software asset management platform in the sale of a large minority interest to a private equity ﬁrm
Represented a private equity ﬁrm in its acquisition of a healthcare software solutions company
Represented a private equity ﬁrm in its acquisition of a company providing software to facilitate forms completion, data collection, and process workﬂow

Recent Insights

Client Highlights

On August 8, 2024, Recursion and Exscientia announced the companies have entered into a definitive agreement, combining Recursion, a leading clinical stage technology-enabled biotech company decoding biology to industrialize drug discovery, with Exscientia, a technology-driven clinical stage drug design and development company, committed to creating more effective medicines for patients, faster. Wilson Sonsini Goodrich & Rosati advised Recursion on the transaction.

Learn More

Client Highlights

On May 31, 2024, Microchip Technology (NASDAQ: MCHP) completed an offering of $1.25 billion aggregate principal amount of convertible senior notes due 2030 in a private transaction. The offering amount included the exercise in full of the option that Microchip had granted to the initial purchasers to purchase up to an additional $150 million of notes. In connection with the offering, Microchip entered into privately negotiated capped call transactions with one or more of the initial purchasers and other financial institutions.

Learn More

View All

Recent Events

Affiliated Programs

Join us for our quarterly event at Silicon Slopes, where we’ll delve into the critical realm of SEC rulings and updates.

Madison Poitras from Moss Adams will discuss the status of the SEC climate disclosure rule and ways to prepare for any outcome. Nathan Robinson from Wilson Sonsini will provide other SEC rulemaking updates, proxy advisor policy changes, and shareholder proposal trends.

Topics of discussion will include cybersecurity disclosure and other expected SEC rulings and activity including artificial intelligence (AI) and human capital.

A panel-style Q&A session will be held at the end of the presentation, so come prepared to ask questions and gain clarity on the latest SEC activity.

Learn More

WSGR Events

The financial services landscape continues to evolve, with recent innovations ranging from embedded finance to the use of AI for enhancing investment strategies. Please join Wilson Sonsini, KPMG, and Mercato Partners for a lunch discussion on topics of import for the fintech ecosystem, including regulatory, industry, and transaction trends in fintech.

Learn More